{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenoviral+Infection&page=4",
    "query": {
      "condition": "Adenoviral Infection",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 144,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenoviral+Infection&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenoviral+Infection&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T03:04:51.542Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04693637",
      "title": "Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Adenovirus Infection",
        "BK Virus Infection",
        "Cytomegalovirus Infections",
        "Epstein-Barr Virus Infections",
        "Human Herpes Virus-6 Infection",
        "JC Virus Infection"
      ],
      "interventions": [
        {
          "name": "Posoleucel (ALVR105)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AlloVir",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-01-15",
      "completion_date": "2023-01-19",
      "has_results": true,
      "last_update_posted_date": "2024-05-09",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Northwest Rectangle",
          "state": "District of Columbia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693637"
    },
    {
      "nct_id": "NCT00109655",
      "title": "Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Oncolytic adenovirus (serotype 5) - CG0070",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cell Genesys",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2005-04",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2008-10-03",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109655"
    },
    {
      "nct_id": "NCT01302418",
      "title": "Collection and Testing of Respiratory Samples",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "QIAGEN ResPlex II Advanced Panel",
        "Influenza A",
        "Respiratory Syncytial Virus Infections",
        "Infection Due to Human Parainfluenza Virus 1",
        "Parainfluenza Type 2",
        "Parainfluenza Type 3",
        "Parainfluenza Type 4",
        "Human Metapneumovirus A/B",
        "Rhinovirus",
        "Coxsackie Virus/Echovirus",
        "Adenovirus Types B/C/E",
        "Coronavirus Subtypes 229E",
        "Coronavirus Subtype NL63",
        "Coronavirus Subtype OC43",
        "Coronavirus Subtype HKU1",
        "Human Bocavirus",
        "Artus Influenza A/B RT-PCR Test",
        "Influenza B"
      ],
      "interventions": [
        {
          "name": "artus Influenza A/B RT-PCR Test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "QIAGEN Gaithersburg, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 272,
      "start_date": "2011-02",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 5,
      "location_summary": "Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01302418"
    },
    {
      "nct_id": "NCT01095224",
      "title": "Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "rAd35 Env A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 Env A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 Env B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 180,
      "start_date": "2010-09",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01095224"
    },
    {
      "nct_id": "NCT01443936",
      "title": "Experimental AD4-H5-VTN Vaccine in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "H5N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Ad4-H5-VTN vaccination-tonsillar route",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad4-H5-vaccination-oral route",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 96,
      "start_date": "2011-09-14",
      "completion_date": "2019-04-24",
      "has_results": false,
      "last_update_posted_date": "2019-12-16",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443936"
    },
    {
      "nct_id": "NCT06620003",
      "title": "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "cAd3-Marburg Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Albert B. Sabin Vaccine Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-04-14",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 7,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06620003"
    },
    {
      "nct_id": "NCT00486408",
      "title": "Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MRKAd5 HIV-1 gag/pol/nef",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2007-07",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486408"
    },
    {
      "nct_id": "NCT05271318",
      "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Platinum-refractory Ovarian Carcinoma",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin",
        "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin",
        "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin"
      ],
      "interventions": [
        {
          "name": "TILT-123",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegylated liposomal doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TILT Biotherapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2022-05-17",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • New York, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05271318"
    },
    {
      "nct_id": "NCT05864118",
      "title": "Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Respiratory pathogen panel PCR test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "COVID-19 antibody test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2023-08-21",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05864118"
    },
    {
      "nct_id": "NCT04776317",
      "title": "Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "ChAdV68-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ChAdV68-S-TCE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAM-LNP-S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAM-LNP-S-TCE",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium Chloride, 0.9%",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 81,
      "start_date": "2021-03-25",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-10-06T03:04:51.542Z",
      "location_count": 4,
      "location_summary": "Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04776317"
    }
  ]
}